Showing results (51-60 of 139) with videos related to

Sort By:
Pageof 14
Investigational New Drugs|November 4, 2021
A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patientsThomas Yau, Paul N M Cheng, Joanne Chiu, et al.
Expert Review of Gastroenterology & Hepatology|March 5, 2021
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with SorafenibJosephine Tsang, Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, et al.
Advances in Therapy|May 20, 2020
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular CarcinomaRobin K Kelley, Patrick Mollon, Jean-Frédéric Blanc, et al.
Journal of Geriatric Oncology|April 20, 2023
Recommendations of the International Society of Geriatric Oncology on skin cancer management in older patientsAgata Rembielak, Thomas Yau, Baran Akagunduz, et al.
Pathology Oncology Research : POR|August 21, 2009
PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic successHilda Wong, Thomas Yau, Pierre Chan, et al.
ANZ Journal of Surgery|October 6, 2012
Outcome of laparoscopic versus open hepatectomy for colorectal liver metastasesTan To Cheung, Ronnie T P Poon, Wai Key Yuen, et al.
Cancer|August 25, 2009
The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolizationThomas Yau, Tzy Jyun Yao, Pierre Chan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 12, 2014
Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international databaseMatan J Cohen, Izhar Levy, Orly Barak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2011
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamicsThomas Yau, Pei-Jer Chen, Pierre Chan, et al.
Oncology|December 22, 2007
Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinomaThomas Yau, Pierre Chan, Hilda Wong, et al.
Pageof 14